WO1998013501A3 - 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales - Google Patents

3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales Download PDF

Info

Publication number
WO1998013501A3
WO1998013501A3 PCT/US1997/016718 US9716718W WO9813501A3 WO 1998013501 A3 WO1998013501 A3 WO 1998013501A3 US 9716718 W US9716718 W US 9716718W WO 9813501 A3 WO9813501 A3 WO 9813501A3
Authority
WO
WIPO (PCT)
Prior art keywords
viruses
promoter region
polymerase gene
attenuation
genomic promoter
Prior art date
Application number
PCT/US1997/016718
Other languages
French (fr)
Other versions
WO1998013501A2 (en
Inventor
Mohinderjit S Sidhu
Stephen A Udem
Joanne M Tatem
Brian R Murphy
Valerie B Randolph
Original Assignee
American Cyanamid Co
Us Health
Mohinderjit S Sidhu
Stephen A Udem
Joanne M Tatem
Brian R Murphy
Valerie B Randolph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co, Us Health, Mohinderjit S Sidhu, Stephen A Udem, Joanne M Tatem, Brian R Murphy, Valerie B Randolph filed Critical American Cyanamid Co
Priority to CA002265554A priority Critical patent/CA2265554A1/en
Priority to JP10515749A priority patent/JP2000517194A/en
Priority to AU44278/97A priority patent/AU4427897A/en
Priority to EP97942613A priority patent/EP0932684A2/en
Priority to BR9712138-0A priority patent/BR9712138A/en
Publication of WO1998013501A2 publication Critical patent/WO1998013501A2/en
Publication of WO1998013501A3 publication Critical patent/WO1998013501A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Isolated, recombinantly-generated, attenuated, nonsegmented, negative-sense, single stranded RNA viruses of the Order Mononegavirales having at least one attenuating mutation in the 3' genomic promoter region and having at least one attenuating mutation in the RNA polymerase gene are described. Vaccines are formulated comprising such viruses and a physiologically acceptable carrier. The vaccines are used for immunizing an individual to induce protection against a nonsegmented, negative-sense, single stranded RNA virus of the Order Mononegavirales.
PCT/US1997/016718 1996-09-27 1997-09-19 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales WO1998013501A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002265554A CA2265554A1 (en) 1996-09-27 1997-09-19 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
JP10515749A JP2000517194A (en) 1996-09-27 1997-09-19 Mutations in the 3 'genomic promoter region and polymerase gene responsible for attenuation in the virus of the eye termed Mononegavirales
AU44278/97A AU4427897A (en) 1996-09-27 1997-09-19 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
EP97942613A EP0932684A2 (en) 1996-09-27 1997-09-19 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
BR9712138-0A BR9712138A (en) 1996-09-27 1997-09-19 Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2682396P 1996-09-27 1996-09-27
US60/026,823 1996-09-27

Publications (2)

Publication Number Publication Date
WO1998013501A2 WO1998013501A2 (en) 1998-04-02
WO1998013501A3 true WO1998013501A3 (en) 1998-08-13

Family

ID=21833976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016718 WO1998013501A2 (en) 1996-09-27 1997-09-19 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales

Country Status (8)

Country Link
EP (1) EP0932684A2 (en)
JP (1) JP2000517194A (en)
KR (1) KR20000048628A (en)
CN (1) CN1232504A (en)
AU (1) AU4427897A (en)
BR (1) BR9712138A (en)
CA (1) CA2265554A1 (en)
WO (1) WO1998013501A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
EP1015594A1 (en) * 1997-09-19 2000-07-05 American Cyanamid Company Attenuated respiratory syncytial viruses
CN1600852A (en) * 1998-03-26 2005-03-30 惠氏控股有限公司 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B
WO1999063064A1 (en) * 1998-06-03 1999-12-09 American Cyanamid Company Novel methods for rescue of rna viruses
DE69937999T2 (en) 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag INTERFERON INDUCING GENETICALLY MODIFIED ATTENUATED VIRUSES
DK1086207T3 (en) 1998-06-12 2007-05-29 Sinai School Medicine New methods and inteferon-deficient substrates for the propagation of viruses
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE60124098T2 (en) * 2000-06-23 2007-04-05 Wyeth Holdings Corp. Modified Morbillivirus V proteins
US7361496B1 (en) 2000-08-02 2008-04-22 Wyeth Rescue of mumps virus from cDNA
PL213926B1 (en) 2001-01-19 2013-05-31 Vironovative Bv A virus causing respiratory tract illness in susceptible mammals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
CN101098958A (en) 2002-02-21 2008-01-02 免疫医疗疫苗公司 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
JP2005523698A (en) 2002-04-26 2005-08-11 メディミューン・ヴァクシンズ・インコーポレーテッド Multiple plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1375670B1 (en) 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
EP1375512B1 (en) * 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
ATE469170T1 (en) * 2003-03-28 2010-06-15 Medimmune Llc COMPOSITIONS AND METHODS USING THE RESPIRATORY SYNCYTIAL VIRUS SUBGROUP B STRAIN 9320
EP2494987A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
CA2816222A1 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP1697521B1 (en) 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus
ES2454266T3 (en) 2004-05-25 2014-04-10 Medimmune, Llc Variants of hemagglutinin and influenza neuraminidase
EP3332803B1 (en) 2004-06-01 2021-09-08 Icahn School of Medicine at Mount Sinai Genetically engineered swine influenza virus and uses thereof
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
ES2527503T3 (en) 2005-03-08 2015-01-26 Medimmune, Llc Reordering influenza viruses
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
US20060286591A1 (en) 2005-06-21 2006-12-21 Medimmune Vaccines, Inc. Methods and compositions for expressing negative-sense viral RNA in canine cells
NZ595736A (en) 2005-12-02 2013-05-31 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
JP5491173B2 (en) 2006-04-19 2014-05-14 メディミューン，エルエルシー Methods and compositions for expressing minus-strand viral RNA in canine cells
WO2008133701A1 (en) 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
CN101983069B (en) 2006-08-09 2014-07-16 米迪缪尼有限公司 Influenza hemagglutinin and neuraminidase variants
JP2010514424A (en) * 2006-12-22 2010-05-06 ザ ペン ステート リサーチ ファウンデーション Modified polymerases and attenuated viruses and methods for their use
JP5666905B2 (en) 2007-06-18 2015-02-12 メディミューン，エルエルシー Influenza B virus having alterations in hemagglutinin polypeptide
AU2009268576B2 (en) 2008-07-11 2014-03-27 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
KR20110081282A (en) 2008-11-05 2011-07-13 와이어쓰 엘엘씨 Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
CN102361649A (en) 2009-02-12 2012-02-22 米迪缪尼有限公司 Influenza hemagglutinin and neuraminidase variants
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
WO2011014645A1 (en) 2009-07-30 2011-02-03 Mount Sinai School Of Medicine Of New York University Influenza viruses and uses thereof
KR20130075732A (en) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 Influenza virus vaccines and uses thereof
EP2420242A1 (en) 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
CA2838614A1 (en) 2011-06-08 2013-04-04 Vishwas Joshi Two plasmid mammalian expression system
CN103906843B (en) * 2011-06-08 2016-12-07 维什瓦斯·乔希 Double-mass model mammalian expression systems
AU2012312529B2 (en) 2011-09-20 2018-01-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
WO2014099931A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CN111218429A (en) 2013-03-14 2020-06-02 西奈山伊坎医学院 Newcastle disease virus and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3110443A4 (en) 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
AU2016222962B2 (en) 2015-02-26 2020-05-21 Boehringer Ingelheim Vetmedica Gmbh Bivalent swine influenza virus vaccine
EP3331554B1 (en) 2015-08-03 2022-05-11 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
US10548966B2 (en) 2015-08-20 2020-02-04 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
WO2017031401A2 (en) 2015-08-20 2017-02-23 University Of Rochester Ns1 truncated virus for the development of canine influenza vaccines
MA42656A (en) 2015-08-20 2018-06-27 Univ Cornell LIVE ATTENUATED VACCINE CONTAINING VIRAL POLYMERASE MUTATIONS FOR THE TREATMENT AND PREVENTION OF CANINE INFLUENZA VIRUS
WO2017210528A1 (en) 2016-06-03 2017-12-07 University Of Rochester Equine influenza virus live-attenuated vaccines
BR112018075032A2 (en) 2016-06-15 2019-03-26 Icahn School Of Medicine At Mount Sinai influenza virus hemagglutinin proteins and their use
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
MX2020008927A (en) 2018-02-27 2021-01-08 Univ Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses.
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
CN113905759A (en) 2019-02-27 2022-01-07 罗切斯特大学 Multivalent attenuated live influenza vaccine for prevention and control of Equine Influenza Virus (EIV)
US11103576B1 (en) 2020-06-15 2021-08-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Measles virus vaccine expressing SARS-COV-2 protein(s)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440219A1 (en) * 1990-02-02 1991-08-07 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN cDNA corresponding to the genome of negative-strand RNA viruses, and process for the production of infectious negative-strand RNA viruses
EP0540135A2 (en) * 1991-10-14 1993-05-05 The Kitasato Institute Attenuated measles vaccine virus strain containing specific nucleotide sequence and a method for its absolute identification
EP0567100A1 (en) * 1992-04-21 1993-10-27 American Cyanamid Company Mutant respiratory syncytial virus (RSV) vaccines containing same and methods of use
WO1993021310A1 (en) * 1992-04-21 1993-10-28 American Home Products Corporation Attenuated respiratory syncytial virus vaccine compositions
WO1993021306A1 (en) * 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Genetically engineered attenuated viruses
EP0702085A1 (en) * 1994-07-18 1996-03-20 Akzo Nobel N.V. Recombinant infectious non-segmented negative strand RNA virus

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440219A1 (en) * 1990-02-02 1991-08-07 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN cDNA corresponding to the genome of negative-strand RNA viruses, and process for the production of infectious negative-strand RNA viruses
EP0540135A2 (en) * 1991-10-14 1993-05-05 The Kitasato Institute Attenuated measles vaccine virus strain containing specific nucleotide sequence and a method for its absolute identification
WO1993021306A1 (en) * 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Genetically engineered attenuated viruses
EP0567100A1 (en) * 1992-04-21 1993-10-27 American Cyanamid Company Mutant respiratory syncytial virus (RSV) vaccines containing same and methods of use
WO1993021310A1 (en) * 1992-04-21 1993-10-28 American Home Products Corporation Attenuated respiratory syncytial virus vaccine compositions
EP0702085A1 (en) * 1994-07-18 1996-03-20 Akzo Nobel N.V. Recombinant infectious non-segmented negative strand RNA virus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COLLINS P.L. ET AL.: "Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.", PROC. NATL. ACAD. SCI. USA, vol. 92, December 1995 (1995-12-01), pages 11563 - 11567, XP002066592 *
CROWE J.E. ET AL.: "Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.", VIRUS GENES, vol. 13, no. 3, February 1996 (1996-02-01), pages 269 - 273, XP002066591 *
MORI T. ET AL.: "Molecular cloning and complete nucleotide sequence of genomic RNA of the AIK-C strain of attenuated measles virus.", VIRUS GENES, vol. 7, no. 1, 1993, pages 67 - 81, XP002051752 *
RADECKE F. ET AL.: "RESCUE OF MEASLES VIRUSES FROM CLONED DNA", EMBO JOURNAL, vol. 14, no. 23, 1 December 1995 (1995-12-01), pages 5773 - 5784, XP002022952 *
STOKES A. ET AL.: "The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses(cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3).", VIRUS RESEARCH, vol. 30, 1993, pages 43 - 52, XP002051711 *

Also Published As

Publication number Publication date
WO1998013501A2 (en) 1998-04-02
AU4427897A (en) 1998-04-17
BR9712138A (en) 2000-01-18
JP2000517194A (en) 2000-12-26
EP0932684A2 (en) 1999-08-04
CA2265554A1 (en) 1998-04-02
KR20000048628A (en) 2000-07-25
CN1232504A (en) 1999-10-20

Similar Documents

Publication Publication Date Title
WO1998013501A3 (en) 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
BR9812232A (en) Human respiratory syncytial virus (rsv) human subgroup b, isolated, recombinantly generated, attenuated, vaccine, process to immunize an individual to induce protection against rsv subgroup b, composition, process to produce attenuated infectious rsv subgroup b, and isolated acid molecule nucleic
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
FR2716893B1 (en) Recombinant viruses, their preparation and their therapeutic use.
IE842668L (en) Method of inhibiting propagation of virus and anti-viral¹agent
CA2011878A1 (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
WO2004014314A3 (en) Methods and compositions concerning poxviruses and cancer
WO1995032298A3 (en) Safe vectors for gene therapy
WO2001068103A3 (en) Treatment of herpes infection using immunomodulatory polynucleotide sequences
WO1999029717A3 (en) Postweaning multisystemic wasting syndrome virus from pigs
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CA2186044A1 (en) Novel mutated viruses, anti-viral compounds and novel methods of making vaccines
EP1005535A4 (en) Attenuation of negative stranded rna viruses by rearrangement of their genes and uses thereof
GB9306731D0 (en) Vaccines
MXPA03000061A (en) Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof.
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
EP0745090A1 (en) Oligonucleotides with anti-respiratory syncytial virus activity
OA09664A (en) Virus/herbicide-resistance genes, processes for the preparation thereof and the use thereof
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
BR9815285A (en) Alphaviruses for paramyxoviruses vaccine
CA2329510A1 (en) Promoter sequence which is expressed in anthers and in pollen
WO2001077358A3 (en) Herpes viruses for immune modulation
AU4425397A (en) Antisense gene therapy for rna viruses
WO1999049017A3 (en) Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
AU5118199A (en) Avian leukosis virus subgroup j envelope gene product for diagnosis and vaccine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97198321.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997942613

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2265554

Country of ref document: CA

Ref document number: 2265554

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09269367

Country of ref document: US

ENP Entry into the national phase

Ref document number: 1998 515749

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997002569

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997942613

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997002569

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997942613

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997002569

Country of ref document: KR